IV Placebo: Clinical Trials

5 trials of IV Placebo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 withdrawn, 1 terminated. 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Withdrawn 2, Terminated 1
Phase 31Terminated 1

Follow IV Placebo: new trials by email Literature Review of IV Placebo trials Research Report on IV Placebo

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
IV Ganaxolone, IV Placebo - Status Epilepticus
Phase 2WithdrawnMarinus Pharmaceuticals2023-04-012024-05-07
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
natalizumab IV, natalizumab SC, IV Placebo - Relapsing-Remitting Multiple Sclerosis
Phase 2CompletedBiogen2902011-08-012015-08-21
Treatment Interruption of Natalizumab
natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedBiogen1752010-03-012013-09-19
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Methylprednisolone, ACTH, IV placebo - Multiple Sclerosis
Phase 2 / Phase 3TerminatedNeurologique Foundation, Inc.302009-10-012016-03-22
Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor
Propranolol, IV Placebo - Dysfunctional Labor
Phase 2WithdrawnUniversity of California, Irvine2004-01-012019-02-27

Conditions studied

Multiple Sclerosis, Relapsing-Remitting (2)  ·  Dystocia (1)  ·  Multiple Sclerosis (1)  ·  Recurrence (1)  ·  Sclerosis (1)  ·  Status Epilepticus (1)

Sponsors

Biogen (2)  ·  Marinus Pharmaceuticals (1)  ·  Neurologique Foundation, Inc. (1)  ·  University of California, Irvine (1)

Countries

United States (3)  ·  Germany (2)  ·  Spain (2)  ·  Belgium (1)  ·  France (1)  ·  Italy (1)

Top investigators

Daniel Kantor, MD (1)  ·  Leah R Battista, MD (1)

Results publications

PMID 26049148, PMID 38648580